PTC Therapeutics Nets Brazilian Approval for Familial Partial Lipodystrophy Drug

ANVISA, Brazil’s health regulatory body, has approved PTC Therapeutics’ Waylivra for the treatment of family partial lipodystrophy (FPL). The approval marks the first of its kind worldwide for the disease. The drug is already approved in Brazil and the EU for the treatment of patients living with Familial Chylomicronemia Syndrome.

According to Stuart Peltz, CEO of PTC, “Waylivra’s approval as the first treatment for FPL is an important milestone for FPL patients in Brazil. This approval is another example of PTC leveraging its strong capabilities in Latin America to bring first-of-its-kind transformational therapies to patients with high unmet needs”

To read more, click here.

(Source: Pharmaceutical Technology, December 2^nd, 2022)